BiotechTube

FYB203 2 mg (0.05 mL of 40 mg/mL)

ApprovedCompleted
0 views this week 0 watching💤 Quiet
Interest: 33/100
33
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Age-Related Macular Degeneration

Conditions

Age-Related Macular Degeneration, Branch Retinal Vein Occlusion with Macular Edema, Central Retinal Vein Occlusion with Macular Edema, Diabetic Macular Edema, Diabetic Retinopathy

Trial Timeline

Sep 20, 2024 → Oct 8, 2024

NCT ID
NCT06708637

About FYB203 2 mg (0.05 mL of 40 mg/mL)

FYB203 2 mg (0.05 mL of 40 mg/mL) is a approved stage product being developed by Formycon AG for Age-Related Macular Degeneration. The current trial status is completed. This product is registered under clinical trial identifier NCT06708637. Target conditions include Age-Related Macular Degeneration, Branch Retinal Vein Occlusion with Macular Edema, Central Retinal Vein Occlusion with Macular Edema.

What happened to similar drugs?

20 of 20 similar drugs in Age-Related Macular Degeneration were approved

Approved (20) Terminated (3) Active (0)
✅FYB201 0.5 mg (0.05 mL of 10 mg/mL)Formycon AGApproved
✅ranibizumabNovartisApproved
✅Ranibizumab (Lucentis) + 0.5mg ranibizumabNovartisApproved
✅ranibizumabNovartisApproved
✅RanibizumabNovartisApproved
✅Intraviteal Ranibizumab 0.5mgNovartisApproved
✅Verteporfin for injectionNovartisApproved

Hype Score Breakdown

Clinical
20
Activity
8
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06708637ApprovedCompleted

Competing Products

20 competing products in Age-Related Macular Degeneration

See all competitors
ProductCompanyStageHype Score
CLS-AX + Anti-VEGFClearside BiomedicalPhase 1/2
22
CLS-AX + AfliberceptClearside BiomedicalPhase 2
25
Eylea + ALT-L9AlteogenPhase 1
29
FYB201 0.5 mg (0.05 mL of 10 mg/mL)Formycon AGApproved
33
UBX1325 injection 50 μL + EYLEA® (aflibercept) Injection 2 mg (0.05mL)Unity BiotechnologyPhase 2
25
DS-7080a + RanibizumabDaiichi SankyoPhase 1
29
Fovista® + bevacizumab + ranibizumab + afliberceptAstellas PharmaPhase 2
27
MA09-hRPEAstellas PharmaPre-clinical
26
volociximabAstellas PharmaPhase 1
29
Avacincaptad PegolAstellas PharmaPhase 1
29
Avacincaptad Pegol + Avastin + Lucentis + EyleaAstellas PharmaPhase 2
27
Avacincaptad PegolAstellas PharmaPhase 1
29
E10030 + ranibizumab + E10030 sham intravitreal injectionAstellas PharmaPhase 3
32
E10030Astellas PharmaPhase 1
29
ASP7317 + tacrolimus + trimethoprim-sulfamethoxazole + Acyclovir + NystatinAstellas PharmaPhase 1
36
Sub-retinal transplantation of MA09-hRPE cells + tacrolimus and mycophenolate mofetil + Placebo tacrolimus and mycophenolate mofetilAstellas PharmaPhase 2
27
Avacincaptad Pegol + LucentisAstellas PharmaPhase 2
35
E10030 + bevacizumab or aflibercept + E10030 sham injectionAstellas PharmaPhase 3
32
Fovista® (anti-PDGF BB) plus anti-VEGFAstellas PharmaPhase 2
27
E10030 plus Lucentis + LucentisAstellas PharmaPhase 2
35